Daniel J. Rader

Comparison of intensive and moderate lipid lowering with statins after acute coronary symptoms

A. Skene, M. Pfeffer, J. Rouleau, 2004 .

Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

E. Braunwald, K. A. Hill, Daniel J. Rader, 2004, The New England journal of medicine.

Comparison of intensive and moderate lipid lowering with statins after acute coronary symptoms

A. Skene, M. Pfeffer, J. Rouleau, 2004 .

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

Jennifer G. Robinson, J. D. Jordan, G. Molenberghs, 2016, Journal of the American Heart Association.

University of Pennsylvania Department of Physiology Retreat

T. Jongens, S. Hugelier, Kahealani Uehara, 2022 .

Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.

C. Cannon, D. Rader, M. Banach, 2018, Kidney international.